MeCure Industries Plc has launched its unaudited {financial} outcomes for the second quarter ended June 30, 2025, reporting a pre-tax revenue of N3.093 billion, representing a formidable 634% year-on-year (YoY) progress in comparison with Q2 2024.
This robust second-quarter efficiency pushed H1 2025 pre-tax revenue to N3.903 billion, marking a 192% YoY enhance and already 18% larger than the corporate’s full-year 2024 pre-tax revenue.
A more in-depth take a look at the financials exhibits that the spectacular bottom-line progress in Q2 was largely pushed by a pointy enhance in income:
One other contributing issue to the robust revenue was the slower progress in the price of gross sales relative to income:
Regardless of larger overheads in Q2 2025, the corporate confirmed higher price self-discipline:
As of the shut of buying and selling on August 6, 2025, MeCure’s inventory was priced at N15.85, reflecting a 14% year-to-date acquire.
MeCure Industries’ Q2 2025 efficiency marks a big turnaround — pushed by booming gross sales in acute and OTC segments, improved price effectivity, and stronger gross and working margins.
The corporate’s aggressive growth, largely funded by debt, has heightened its leverage danger.
Nevertheless, it’s producing enough working revenue to service this debt, as mirrored within the improved curiosity protection ratio of two.49x.
